Clinical Trials
17
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)⢠Click on a phase to view related trials
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
- Conditions
- Prevention of Esophageal VaricesCirrhosisNASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 357
- Registration Number
- NCT04365868
- Locations
- đşđ¸
University of Alabama at Birmingham, Birmingham, Alabama, United States
đşđ¸Digestive Health Specialists, Dothan, Alabama, United States
đşđ¸The Institute for Liver Health, Chandler, Arizona, United States
A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04332432
- Locations
- đşđ¸
Inland Empire Clinical Trials, Rialto, California, United States
đşđ¸Clinical Pharmacology of Miami, Inc, Miami, Florida, United States
đşđ¸Texas Liver Institute, San Antonio, Texas, United States
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT02462967
- Locations
- đşđ¸
Cedars Sinai Medical Center, Los Angeles, California, United States
đşđ¸University of California Davis Medical Center, Sacramento, California, United States
đşđ¸University of California San Diego Medical Center, San Diego, California, United States
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02421094
- Locations
- đşđ¸
Brooke Army Medical Center, Fort Sam Houston, Texas, United States
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT02407041
- Locations
- đşđ¸
Brooke Army Medical Ctr., San Antonio, Texas, United States
- Prev
- 1
- 2
- Next
News
Galectin Therapeutics Secures $10 Million Credit Line to Advance MASH Cirrhosis Program Through 2026
Galectin Therapeutics announced a new $10 million unsecured credit line from Chairman Richard E. Uihlein to fund operations through June 2026.
Liver Cirrhosis Pipeline Shows Strong Growth with 30+ Therapies in Development Across Multiple Clinical Phases
DelveInsight's 2025 pipeline analysis reveals over 30 companies developing 30+ liver cirrhosis therapies, with promising candidates like Rezdiffra, efruxifermin, and belapectin showing significant clinical progress.
Hepatology Review: FDA Updates, Viral Hepatitis Research, and MASH Advancements in December 2024
⢠The FDA updated safety information for obeticholic acid (Ocaliva) regarding liver injury risk in primary biliary cholangitis (PBC) patients without cirrhosis. ⢠Breakthrough Therapy designation was granted to tobevibart and elebsiran by the FDA and EMA for chronic hepatitis delta (CHD) treatment, based on Phase 2 SOLSTICE trial data. ⢠Atea Pharmaceuticals reported positive Phase 2 results for bemnifosbuvir and ruzasvir in hepatitis C virus (HCV) treatment, achieving a 98% SVR12 rate. ⢠Belapectin, from Galectin Therapeutics, in MASH cirrhosis and portal hypertension, did not meet its primary endpoint in the Phase 2b/3 NAVIGATE trial.
Belapectin Shows Significant Reduction in New Varices in U.S. MASH Cirrhosis Patients
Belapectin demonstrates a statistically significant 68.1% reduction in the incidence of new varices compared to placebo in U.S. patients with MASH cirrhosis and portal hypertension.
Galectin Therapeutics' Belapectin Fails to Meet Primary Endpoint in MASH Cirrhosis Trial
Galectin Therapeutics' NAVIGATE trial of belapectin in MASH cirrhosis patients with portal hypertension did not meet its primary endpoint of preventing varices.